National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population.
about
Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and chinaA systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysisCollaboration between Hepatologists and Primary Care Physicians in Treating Patients with Chronic Hepatitis C.Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography.Current management of patients with hepatocellular carcinoma.Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.Treatment of interferon-alpha for chronic hepatitis C.Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis CCost of illness of non-alcoholic liver cirrhosis in Japan: A time trend analysis and future projections.Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma.Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma.Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients.Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan.Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004.The emerging importance of chronic hepatitis C infection in Asian Americans.Follow up of the 987 blood donors found with hepatitis C virus infection over 9-18 years.Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment: Study on 1019 carriers followed for 5-10 years.Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels.An updated report of the trends in cancer incidence and mortality in Japan.
P2860
Q27003291-C64BB21C-22C1-4EFB-BCA6-CE784B127764Q30403548-3A3E7703-88E0-4149-9259-0467BA2F7BE7Q30418176-176D56D7-C26C-4515-98E8-1827F356EBB2Q30479629-08E2C4B1-5837-4D7C-9C87-D33C38986E90Q34461341-DAC30536-8FB4-4EF9-ACAA-A955649A034CQ35022767-5325195C-33F3-4962-A342-15B4A4C13EA5Q35872121-C17F43D5-F742-46E6-B29F-018BDAC06A48Q35895363-A21DC853-D57E-4B04-A1D0-EAD9A4876AF6Q36349997-6E65A4EE-40D7-4C9B-97CB-456362EECFE6Q36491803-DFFAEA20-BF01-49F6-B4E8-37C01D941E0CQ36645372-7765D4CD-C5D8-40D9-909E-9DD81BC8C017Q36973392-577D7130-0BAB-413E-95DB-233F55E9E842Q37651899-DA921C53-4CA2-4859-AC0E-53F3A8BC676EQ38684724-750BF9D9-0935-4258-9365-27D0486372BEQ40473920-7DA6A69C-273E-4547-B59B-DAC2E4367C51Q40631323-172B7176-D182-41E7-8ED6-0941393342E4Q41717354-76B6A554-0CF3-4034-A6A3-52F08158C3FEQ42175640-A1A5845E-79A0-48EE-95AE-908E282DD00EQ42212457-CEC545F4-00D3-4B4A-8C84-8B552B93CB95Q42244766-409DA89A-5B1D-4490-A878-361276209E15Q42260526-3CC65B9A-E229-4345-A675-06EB2FF3FF53Q42276777-89326B60-03D3-4DB6-B76B-B435F73ACF59Q42283380-47D1BE1B-CEDC-4A44-9BE4-F42E878C4D80Q43036643-645BFF44-F96A-4416-88A7-3A867203EE7AQ43040333-51C6F64D-25D2-4D4E-A382-C7BC2D4B13D6Q43046540-CE08CCE2-9384-4058-BA4F-AEC693701D18Q44600956-6CB40636-343C-446C-A3BE-96BF0B5190CCQ45359079-6F74B27A-4864-427F-9249-F71771268897Q45401946-02C77625-33DA-4E46-BE12-1CB030AA8FE2Q45971639-3AAF9C02-A799-4B9C-BABE-53BC2AD3BEE6Q51209226-7A567F21-2D55-4F82-AC8A-48F03FE310BD
P2860
National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
National prevention of hepatoc ...... ion in the general population.
@en
type
label
National prevention of hepatoc ...... ion in the general population.
@en
prefLabel
National prevention of hepatoc ...... ion in the general population.
@en
P2093
P356
P1433
P1476
National prevention of hepatoc ...... ion in the general population.
@en
P2093
Hiroshi Yoshizawa
Junko Tanaka
Yuzo Miyakawa
P356
10.1159/000087257
P577
2006-01-01T00:00:00Z